Navigation Links
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Date:9/24/2008

II studies of ANA598 during 2009; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended June 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
2. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
7. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
8. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
11. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... is a hollow needle commonly used with a syringe ... extract fluids from it. A hypodermic needle is used ... that cannot be ingested. Hypodermic needles are broadly classified ...
(Date:7/11/2014)... -- On Thursday, July 10, 2014, ... Jones Industrial Average finished the day 0.42% lower at 16,915.07, ... losses were broad based as eight out of ten sectors ... Sector Index ended the day at 711.88, down 0.02%, while ... Investor-Edge has initiated coverage on the following equities: Covidien PLC ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... OAK BROOK, Ill. , July 12 The University ... agreement to Ascent, a leader in health care resource sustainability. The agreement, ... 1, 2010 . Under the contract, Ascent will offer single-use device (SUD) ... , , , ...
... July 12 ( http://www.myprgenie.com ) -- Medrium, Inc., one ... announced it has signed a partnership agreement with RelayHealth to use ... LabCorp and to provide LabCorp results to physicians utilizing the Medrium ... , ...
Cached Medicine Technology:University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 2University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 3Medrium Partners With RelayHealth 2Medrium Partners With RelayHealth 3
(Date:7/13/2014)... editorial published today in The Lancet Neurology ... consideration the long term neurological problems that repeated ... most common form of sports-related traumatic brain injury ... may include dementia, amyotrophic lateral sclerosis, and other ... is perhaps more concerning, is that even when ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway ... opening up potential new therapeutic strategies for an ... is a chronic inflammatory disorder of the esophagus. ... certain foods and an over-accumulation in the esophagus ... the body,s immune system). EoE can cause a ...
(Date:7/13/2014)... July 13, 2014 The North American water ... in 2013 to $5,450 million by 2018, at a CAGR ... market is expanding at a rapid pace in North America. ... tightening laws on water & wastewater storage and collection, and ... The market is expanding at a healthy rate in Canada, ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... Programs for Eating Disorders,( http://www.remudaranch.com ), the nation,s ... surround the nation,s obsession,with dieting. As the dieting ... Americans continue to lose and gain weight in ... cycling may elevate blood pressure,reduce good cholesterol, deplete ...
... Medical Technologies,Inc., an innovator of endovascular treatments for ... another patent for its,Pathway PV(TM) Atherectomy System. The ... related to Pathway Medical,s innovative,atherectomy system, which is ... the legs. Pathway Medical has a total of ...
... women to enjoy casual sex just as men always had. ... the UK, the negative feelings reported by women after one-night ... sexual encounters. Her findings (1) are published online in ... , Men are more likely to reproduce and therefore to ...
... hurt. It was like [their father] had met some gal ... she wanted all his money. I felt they didn,t give ... still hurts.", --Remarried wife of 12 years, caring for husband ... Mich.---Late-life remarriage complicates caring for an ailing spouse, according to ...
... June 25 Hologic, Inc.,(Nasdaq: HOLX ) today ... the waiting period under the Hart-Scott-Rodino,Antitrust Improvements Act of ... in connection with Hologic,s previously announced tender offer for,all ... Third Wave,Technologies, Inc. (Nasdaq: TWTI ). The early ...
... looking for qualified candidates and tens of thousands of jobs being created ... graduates and despite the layoff announcements that tend to shock the average ... ... number of available jobs in health care continued to rise through the ...
Cached Medicine News:Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 2Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 3Health News:Was it good for you too? 2Health News:Late-life remarriage: Stepfamilies make caring more complex 2Health News:Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 3
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... The Retinal Acuity Meter (RAM) is the ... to accurately predict RETINAL ACUITY in eyes with ... hand-held, battery operated, and can test each eye ... Optics, Inc. and tested at Columbia University in ...
... The Hoffmann® II Hybrid External Fixation ... next generation in hybrid fixation. It ... surgeons and is designed to offer ... exclusive patented Hoffmann® snap-fit technology. , ...
... add individual components for individual indications. XCaliber ... Made of an innovative composite plastic material, ... much lighter. This means it's easier to ... for the patient. ,Come pre-assembled, packaged sterile, ...
Medicine Products: